AxoGen receives dual analyst support after FDA approval with targets up to $40 (+40 %)

The stock of AxoGen (AXGN) was recently discussed when it broke out to a new multi-year high. The company has shown consistent revenue growth over the past few years and has now reached profitability. AxoGen develops, produces, and distributes tissue grafts and neural "repair solutions” to restore peripheral nerve functions. The business is divided into three segments: extremities, oral/maxillofacial, and head-neck, as well as breast reconstruction. Key revenue drivers include the Avance Nerve Graft and complementary products. Approximately 800...